

# EFE EWORUKE, PH.D

| H: 817-656-7320 | C: 3522144202 | email: efeodia@yahoo.com

## Professional Summary

Epidemiologist, SAS Certified Programmer with experience in government and academic institutions, FDA regulatory training and experience, and excellent communication and writing skills

## Current Position (Aug. 10, 2013 – present)

### **Epidemiologist,**

Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration

### *Highlights:*

Delineating and applying regulatory process to protect public health.

Examining post-market drug study reports, protocols and follow-up correspondence prepared by external organization for regulatory reviews.

Preparation of detailed scientific reviews using the office of surveillance and epidemiology (OSE) procedures and relevant MaPPs and Guidances to inform regulatory decisions. Evaluation of case reports and relevant literature pertinent to adverse events associated with drug use

Clearly and effectively expressing ideas and review findings at division meetings

Designing, planning and execution of drug safety assessments and observational pharmacoepidemiological research projects to inform regulatory decisions associated with the use of drugs and biologic products

Provision of technical assistance pertaining to epidemiological and statistical techniques employed to monitor and evaluate post-marketing drug safety issues

### **Clinical Affiliate Assistant Professor**

Dept. of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL

### *Applied Data Analysis, Interpretation and Reporting of Findings in Pharmacy*

Teaching the data analysis, reporting and interpretation of findings in pharmacy course

- Course work comprise of asking good research questions, application of univariate and multivariate statistical models (mixed models) and interpretation of findings (verbally and written in manuscript format)

Mentoring students on various pharmacoepidemiology projects

### **Contract Employment (2006-2008)**

Feb. 2008 - Jun. 2008      Drug Safety Scientist, Astra Zeneca, Horizon Place, Luton, UK  
Jun. 2007 - Nov. 2007      Pharmacovigilance Scientist, Wyeth Pharmaceuticals, Maidenhead, UK  
Oct.2006 - Jun. 2007      Drug Safety Associate, Pfizer Pharmaceuticals, Walton Oaks, UK

### **Education and Training**

**Ph.D., Pharmaceutical Outcomes and Policy** 2013

University of Florida - Gainesville, FL  
Dissertation: *Nontuberculous Mycobacteria in Cystic Fibrosis*

**Master of Science, Pharmacology** 2006

University of Oxford - London, United Kingdom  
Thesis: Molecular Characterization of Calcium-regulated Proteins in Cardiac Myocytes

**Postgraduate certificate, Pharmacoepidemiology and Pharmacovigilance** 2005

London School of Hygiene and Tropical Medicine - London, United Kingdom  
Project Title: *An overall assessment of the risk-benefit profile of HRT*

**Bachelor of Science, Pharmacy** 2003

University of Benin - Benin-city, Nigeria  
Graduated Summa Cum Laude

### **Software/Programming Skills**

SAS, SPSS, ArcGIS, GeoDa, SatScan  
Microsoft Office Suite, EpiInfo, Word Press

### **Teaching Experience**

*Applied Data Analysis, Interpretation and Reporting of Findings in Pharmacy*  
Teaching the data analysis, reporting and interpretation of findings in pharmacy course  
Mentoring students on various pharmacoepidemiology projects

#### *Evidence-based Pharmacy*

Preparation of discussion guides for in-class sessions  
Leading discussion sessions, ensuring students understand lecture materials  
Grading of final term examinations

### **Research Experience**

**2009 - 2011: Research Assistant**

Risk of Respiratory Syncytial Virus (RSV) Infections and Effects on Disease Prognosis in Children with Cystic Fibrosis (\$403, 952)

Funding Agency: Florida Department of Health, Agency for Health Care Administration

PI: Dr. Almut G. Winterstein

### **Licensure & Certifications**

- 2012: SAS Base Programming
- 2012: Foreign Pharmacy Graduate Equivalence Examination
- 2011: Florida State Pharmacy Intern License
- 2003: Registered Pharmacist, Pharmaceutical Society of Nigeria

### **Academic Awards and Distinctions**

- 2008: University of Florida Alumni Fellowship: Award based on previous academic achievement
- 2005: University of Oxford Departmental Bursary Award: Award based on previous academic achievement
- 2003: Pharmacists Council of Nigeria (PCN) Merit Award: Award for academic excellence and ethical behavior in the graduating class of 2003
- 2001: Pharmaceutical Association of Nigerian Students (PANS) Award: for Academic Excellence & Ethical behavior
- 2001: Departmental Academic Prize for the Best Graduating Student (Department of Pharmacology and Toxicology)
- 2001: Departmental Academic Prize for the Best Graduating Student (Department of Pharmacognosy)
- 2001: Award for Distinction by the final year class
- 2000: University of Benin Scholars (Academic) Award: Best Academic Student (Overall)
- 1999: University of Benin Scholars (Academic) Award: Best Academic Student (Female)

### **Training Awards**

- 2012: Mary Kay Owens fellowship recipient for academic year
- 2012: International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Student Travel Scholarship. \$300
- 2012: PharmaSUG Student Scholarship. 2011
- 2011: University of Florida Dubow fellowship recipient for academic year. \$5,000
- 2011: Cystic fibrosis Foundation Student traineeship. \$1500
- 2010: Cystic fibrosis Foundation Student traineeship. \$1500
- 2009: Epilepsy Foundation Health Student Fellowship. \$3000

### **Publications**

#### ***Peer-reviewed Manuscripts***

Eworuke, E., Q.Y. Lensa Zeng, and A.G. Winterstein. Clinical and socio-demographic factors associated with attention deficit/hyperactivity disorder in patients with cystic fibrosis. *Psychosomatics*. Sep 2014; DOI: 10.1016/j.psych.2014.09.001

Winterstein AG, Eworuke E, Xu D, Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. *Pediatric Pulmonology*. Sep 2012;47

Eworuke E, Hampp C., Arwa S., Winterstein AG. Validity of an algorithm for the identification of preterm infants using Medicaid administrative data. *Pharmacoepidemiol Drug Saf*. Jun 2012;21(6):640-50.

Raymond Iduojemu Ozolua, Eric Kelly Inanemo Omogbai, Efe Odia. Some studies on the haemorrhological effects of indomethacin on male wistar rats. *Haema* 2003; 6(2): 193-196

Paul Mattick, John Parrington, Efe Odia, Alasdair Simpson, Thomas Collins and Derek Terrar. Ca<sup>2+</sup>-stimulated adenylyl cyclase isoform AC1 is preferentially expressed in guinea-pig sino-atrial node cells and modulates the If pacemaker current. *J Physiol* Aug 2007 1;582(Pt 3):1195-203.

### ***Book Chapter***

“Case Example 36: Linking Longitudinal Registry Data to Medicaid Analytical Extract (MAX) Files.” IN: Gliklich RE, Dreyer NA, eds. *Registries for Evaluating Patient Outcomes: A User's Guide*. 3rd ed. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014.  
<http://www.effectivehealthcare.ahrq.gov/registries-guide-3.cfm>

### ***Peer-reviewed Published Abstracts***

Eworuke E., Winterstein AG. Deterministic Linkage between cystic fibrosis registry and Medicaid Analytical Extract Data. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012; 21:(Suppl. 3):396

Eworuke E., Winterstein AG. Drug Utilization Patterns for Routine Therapies in pediatric patients with cystic fibrosis. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012; 21:(Suppl. 3): 474

Eworuke E., Xu Dandan, Schuler P. Palivizumab immunoprophylaxis in children with cystic fibrosis. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 22-26 2012, Barcelona, Spain. *Pharmacoepi Drug Saf* 2012; 21:(Suppl. 3):148

Eworuke E., Kauf TL. Use of time-to-event analyses to define episodes of care in sickle cell disease. ISPOR 16th Annual International Meeting, 21 - 25 May 2011, Baltimore, MD (abstract #PND55).

Eworuke E., Delaney JAC. Maternal predictors of preterm birth: an analysis of US birth data. 3<sup>rd</sup> North American Congress of Epidemiology. Montreal, Canada June 21-24, 2011

Eworuke E., Winterstein AG. Comparing pulmonary-related outcomes for newborn-screened versus conventional-diagnosed infants with cystic fibrosis. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 14-17, 2011, Chicago, USA. *Pharmacoepi Drug Saf* 2011;20:S319

Odia E., Hampp C, Winterstein AG. Validity of an algorithm for the identification of premature infants using Medicaid administrative data. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Brighton, UK, August 19-22, 2010. *Pharmacoepi Drug Saf* 2010;19:S123 (oral presentation)

### ***Submitted Reports***

Odia E., Kauf TL. Cost and Quality of Care in Epilepsy: An episode of care approach. Final Report submitted to the American Epilepsy Foundation. August, 2010 (15 pages)

Winterstein AG, Eworuke E, Xu, Dandan, Schuler P. Risk of respiratory syncytial virus (RSV) Infections and Effects on Disease Progression in Children with Cystic Fibrosis. Final Report submitted to Agency for HealthCare Administration (AHCA). June 2011 (82 pages)

Eworuke E, Winterstein AG. Effectiveness of palivizumab in children with cystic fibrosis. Final Summary report submitted to the Cystic Fibrosis Foundation. February 2012 (30 pages)

## **References**

Almut G. Winterstein, PhD

Professor & Graduate Program Director

Pharmaceutical Outcomes & Policy (POP), College of Pharmacy

Epidemiology, Colleges of Medicine and Public Health & Health Professions

Pamela Schuler, MD

Clinical Associate Professor, Pediatric Pulmonology

University of Florida

Jonathan Shuster, PhD Professor

Department of Health Outcomes and Policy

Director, Research Design and Analysis Program, Clinical and Translational Science Institute

Biostatistician, UF Clinical Research Center, College of Medicine